These proteins—and one in particular known as BRD4—are tempting therapeutic targets, because they use the bromodomain (a stretch of 110 amino acids that give BET proteins their name ...

Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves ...

Further candidates, including inhibitors of acetyl-lysine readers (bromodomain-containing proteins), are undergoing clinical evaluation for efficacy in different cancer settings. Among the various ...

The company’s lead candidate, TT125-802, is a novel small molecule CBP/p300 bromodomain inhibitor designed to block transcriptional resistance pathways that drive drug resistance to targeted ...

Detailed price information for Resverlogix Corp (RVX-T) from The Globe and Mail including charting and trades.

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Pasi A. Jänne, M.D., PhD, a world renowned translational thoracic medical oncologist, to its Scientific Advisory Board (SAB).